ArticleOxidative medicine and cellular longevity2020

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways.

Yun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.